Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 plus exemestane and everolimus versus placebo plus exemestane and everolimus in hormone receptor-positive HER2-negative metastatic breast cancer with bone metastases
2014-002114-23Phase 2Completed
- Sponsor
- Bayer
- Start
- Sep 2014
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing Radium-223 + exemestane + everolimus with Placebo + exemestane + everolimus (2 arms). Primary endpoint: Symptomatic skeletal event-free survival. Started Sep 2014; status: completed.
02
Drugs
radium-223 dichlorideexemestaneeverolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2014-002114-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002114-23.